TY - JOUR
T1 - Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls
AU - Montine, T. J.
AU - Kaye, J. A.
AU - Montine, K. S.
AU - McFarland, L.
AU - Morrow, J. D.
AU - Quinn, J. F.
PY - 2001
Y1 - 2001
N2 - Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.
AB - Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.
UR - http://www.scopus.com/inward/record.url?scp=0034745018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034745018&partnerID=8YFLogxK
M3 - Article
C2 - 11260625
AN - SCOPUS:0034745018
SN - 0003-9985
VL - 125
SP - 510
EP - 512
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 4
ER -